Lentitek Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $973K

  • Investors
  • 9

Lentitek General Information

Description

Developer of gene therapies and gene-modified cell therapies designed to increase lentiviral production yields. The company's platform offers a novel promoter with a proprietary method for producing lentivirus that could improve and enhance the yield of lentiviral vectors, enabling healthcare providers to reduce production costs through triple transfection production.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Floor 3, 1-4 Atholl Crescent
  • Edinburgh EH3 8HA
  • Scotland, United Kingdom
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Floor 3, 1-4 Atholl Crescent
  • Edinburgh EH3 8HA
  • Scotland, United Kingdom

Lentitek Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lentitek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 12-Aug-2026 $973K Completed Startup
5. Angel (individual) 13-Feb-2025 Completed Startup
4. Grant 28-Aug-2024 Completed Startup
3. Angel (individual) 09-May-2023 Completed Startup
2. Grant 10-Jun-2022 $100K $54.8K Completed Startup
1. Angel (individual) 13-Feb-2021 $54.8K $54.8K Completed Startup
To view Lentitek’s complete valuation and funding history, request access »

Lentitek Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary 30,267 $0.000013 $11.87 $11.87 $11.87 11.18%
Ordinary 47,050 $0.000013 $1.14 $1.14 $1.14 17.38%
To view Lentitek’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Lentitek Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene therapies and gene-modified cell therapies designed to increase lentiviral production yields. The comp
Biotechnology
Edinburgh, United Kingdom
10 As of 2026

Oxford, United Kingdom
 

Edinburgh, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Lentitek Competitors (3)

One of Lentitek’s 3 competitors is Oxb, a Corporation company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxb Corporation Oxford, United Kingdom
aTen Therapeutics Venture Capital-Backed Edinburgh, United Kingdom
Antev Formerly VC-backed London, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

Lentitek Patents

Lentitek Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4684024-A1 Expression construct Pending 22-Mar-2023
JP-2026511127-A Expression construct Pending 22-Mar-2023
US-20260265777-A1 Expression construct Pending 22-Mar-2023
WO-2024194651-A1 Expression construct Inactive 22-Mar-2023 C12N15/86

Lentitek Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lentitek Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Equity Gap Angel Group Minority
Old College Capital Venture Capital Minority
Orchard Venture Partners Venture Capital Minority
Scottish Enterprise Growth/Expansion Minority
Shancastle Investments Corporation Minority
You’re viewing 5 of 9 investors. Get the full list »

Lentitek FAQs

  • When was Lentitek founded?

    Lentitek was founded in 2019.

  • Where is Lentitek headquartered?

    Lentitek is headquartered in Edinburgh, United Kingdom.

  • What is the size of Lentitek?

    Lentitek has 10 total employees.

  • What industry is Lentitek in?

    Lentitek’s primary industry is Biotechnology.

  • Is Lentitek a private or public company?

    Lentitek is a Private company.

  • What is the current valuation of Lentitek?

    The current valuation of Lentitek is .

  • What is Lentitek’s current revenue?

    The current revenue for Lentitek is .

  • How much funding has Lentitek raised over time?

    Lentitek has raised $2.6M.

  • Who are Lentitek’s investors?

    Equity Gap, Old College Capital, Orchard Venture Partners, Scottish Enterprise, and Shancastle Investments are 5 of 9 investors who have invested in Lentitek.

  • Who are Lentitek’s competitors?

    Oxb, aTen Therapeutics, and Antev are competitors of Lentitek.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process